Australia's draw is a 43.5% refundable R&D tax offset (for groups under A$20M aggregated turnover), and clinical-trial spend qualifies. But on a gross, cash basis — the number that hits a startup's runway — Latin America runs, in bioaccess®'s program experience, about 35–45% below Australia; the rebate narrows that to roughly 5–15% only when it is fully captured, and only if the sponsor stands up an eligible Australian entity and funds the gross while awaiting the refund. End-to-end start-up is broadly comparable once Australian site governance is included, and choosing Australia does not change how FDA or PMDA assess the data. bioaccess® is the First-in-Human CRO — U.S. regulatory anchoring plus Latin American execution — with no foreign entity to establish. Where Australia is genuinely stronger, we say so: arguably the longest early-phase-to-global-pivotal track record, English-language operations end-to-end, and among the most automated PK-lab infrastructure. Figures as of July 2026; general information, not tax, legal, or regulatory advice.
| Metric | bioaccess® | Australia |
|---|---|---|
| Headline draw | Lowest gross (cash) cost, no foreign entity to establish, and same- or near-U.S. time-zone proximity | 43.5% refundable R&D tax offset for groups under A$20M aggregated turnover (counts a U.S. parent and affiliates); clinical-trial spend is eligible and exempt from the A$4M refund cap |
| Start-up speed | Argentina's ANMAT review runs up to ~62 business days under Disposition 7516/2025, with ethics in parallel (a maximum clock; queries can pause it) | No TGA pre-review under the CTN route — but HREC review typically ~6–8 weeks plus separate, site-by-site governance; end-to-end start-up is broadly comparable |
| Gross (cash) cost | Lowest cost base — in bioaccess®'s program experience, roughly 35–45% below Australia on a gross basis (varies with trial design and exchange rates) | Higher gross cost; the R&D rebate can recover ~43.5% of eligible spend, but only if fully captured |
| Effect of the R&D rebate | No rebate needed — you pay only for work delivered, with no financing lag | Narrows the effective gap to ~5–15%, and in some programs a fully-captured rebate can close or reverse it — but only with an eligible Australian entity, and the sponsor funds the gross and awaits the refund (rebate-advance financing exists, at a cost) |
| Entity requirement | None — contract and start | Generally requires an eligible Australian company below A$20M aggregated turnover, with AusIndustry registration plus local tax and legal advisers |
| Incentive durability | Economics based on execution, not a policy subsidy | An R&DTI redesign has been announced/proposed (not yet legislated) to tighten eligibility from 1 July 2028; FY26/FY27 claims unaffected |
| Distance & time zone from the U.S. | Same or adjacent U.S. time zones; ~3–8 hour flights | ~14–20+ hour travel and a 14–18 hour time difference complicate week-to-week oversight |
| FDA acceptance & data applicability | Data conducted under GCP (ISO 14155 for devices; ICH E6 for drugs) supports the U.S. pathway under 21 CFR 812.28 or 312.120 | Also FDA-accepted; FDA and PMDA assess data applicability to their populations case-by-case, regardless of which region hosts the trial |
| Where it is genuinely stronger | Same region carries later patient-phase work; USD-denominated contracts on a lower cost base | Arguably the longest early-phase-to-global-pivotal track record, English-language operations end-to-end, and among the most automated PK-lab infrastructure |
Comparison uses widely-known category facts about Australia and published US/EU benchmark ranges — not Australia-specific figures. bioaccess® figures reflect our FIH-12™ operating model.
Australia's incentive is real, and for the right company it's the one incentive large enough to change a sourcing decision. But it's a financing mechanism, not a price cut. You fund the full gross cost, run the study on the other side of the world, and recover part of it only after your Australian year-end tax lodgement — and only if you've stood up an eligible Australian entity below A$20M aggregated turnover (a threshold that counts a U.S. parent and affiliates, which is exactly the trap early-stage sponsors miss). On a gross, cash basis — the number that actually hits a startup's runway — Latin America runs, in bioaccess®'s program experience, about 35–45% below Australia; the rebate narrows that to roughly 5–15% only when it is fully captured, and in some programs a fully-captured rebate can close or reverse the gap. Actual deltas vary with trial design, exchange rates, and how much of the rebate is ultimately captured.
The rest of the picture is closer than the marketing suggests, and we'll say so plainly. End-to-end start-up is broadly comparable once Australian site governance is included: Argentina's ANMAT review runs up to ~62 business days under Disposition 7516/2025 (with ethics in parallel), while Australia's CTN route requires no TGA pre-review but typically involves ~6–8 weeks of HREC review plus separate, site-by-site governance. On the regulatory side, FDA and PMDA assess whether foreign data are applicable to their populations case-by-case — that question does not turn on whether you run in Latin America, Australia, or Canada. What Latin America adds is a lower cash-basis cost, no foreign entity to establish, short-haul travel in your own time zones, and the same regional infrastructure that will carry your later patient-phase work. An R&DTI redesign has also been announced/proposed (not yet legislated) that would tighten Australian eligibility from 1 July 2028.
Where Australia is genuinely stronger, we say so: it has arguably the longest track record from early phase into global pivotal programs, English-language operations end-to-end, gold-standard healthy-volunteer units, and among the most automated PK-lab infrastructure — and if you can structure an Australian entity, the rebate is hard to beat. bioaccess® is the better fit when the goal is fast, fundable, FDA-bridgeable human data on a startup budget without standing up a foreign subsidiary. Data is generated under GCP (ISO 14155 for devices; ICH E6 for drugs and biologics) and is eligible for FDA consideration under 21 CFR 812.28 or 312.120 — a case-by-case determination, subject to FDA's data-validation and supporting-information requirements, not a guarantee of acceptance. One U.S. medical-device startup came to bioaccess® after an Australian ethics committee declined its first-in-human study — ethics committees decline studies for many reasons, from local feasibility and insurance to standard-of-care fit, not only safety. After the sponsor addressed the committee's feedback, the program obtained full ethics-committee and regulatory approvals in three Latin American countries and is now enrolling.
Figures on this page are as of July 2026 and are general information, not tax, legal, or regulatory advice; sponsors should confirm current rules with qualified advisers.
It can be — but weigh the whole picture. The 43.5% refundable offset is real for groups under A$20M aggregated turnover (a threshold that counts a U.S. parent), and clinical-trial spend qualifies. To claim it, though, the R&D generally has to run through an eligible Australian company, and the cash only arrives after year-end lodgement — so you fund the full gross cost first. In bioaccess®'s program experience the gross, cash cost in Latin America runs about 35–45% below Australia, and the rebate narrows that to roughly 5–15% only when fully captured. For a lean team, the entity overhead and financing lag often outweigh the headline number. This is general information, not tax advice.
On a gross, cash-contracting basis — the figure that hits your runway — Latin America is, in bioaccess®'s program experience, about 35–45% below Australia (actual deltas vary with trial design and exchange rates). Australia's R&D rebate can recover ~43.5% of eligible spend, which narrows the effective gap to roughly 5–15% and in some programs can close or reverse it — but only if the sponsor sets up an eligible Australian entity and funds the gross while awaiting the refund. bioaccess® compares on gross and treats the rebate as a separate, conditional recovery rather than a price cut.
In most cases, yes. The offset generally requires the R&D to be conducted by an eligible Australian company below A$20M aggregated turnover, so U.S. startups typically incorporate an Australian subsidiary and engage local tax and legal advisers to register the activities and lodge the claim. That overhead — plus the cash-flow lag until year-end lodgement (rebate-advance financing exists, at a cost) — is part of the real cost of the incentive, and it's a burden a 3–5 person team often doesn't want. This is general information, not tax advice.
Yes — foreign clinical data from either region can support a U.S. submission when it meets the applicable requirements (21 CFR 812.28 for devices, 21 CFR 312.120 for drugs, conducted under GCP). Acceptance is determined by the FDA case-by-case, subject to its data-validation and supporting-information requirements, not by the country of origin. Data-applicability questions for agencies like FDA and PMDA are assessed case-by-case regardless of whether the trial runs in Latin America, Australia, or Canada.
…you can and will structure an eligible Australian entity below A$20M aggregated turnover and the cash rebate is central to your funding model, you want English-language operations end-to-end with among the most automated PK-lab infrastructure, or your asset benefits from Australia's long early-phase-to-global-pivotal track record. If instead you want the fastest, lowest-gross-cost route to FDA-bridgeable human data without standing up a foreign subsidiary — close to your time zone, in the same region that carries your later patient phases — bioaccess® in Latin America is built for that.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call